NEWS

Recent News

NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein

World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer,...

NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy with Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS

World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care...

NantKwest Key Opinion Leader Event

KOL Lunch on Phase I & II Clinical Programs Conference Details: Date: Monday, December 2, 2019 from 12:00 PM to 2:00 PM EST This event will feature presentations from Key Opinion Leaders, George Ansstas, MD (Washington University of Medicine, St. Louis), Chaitali...

Archives

Media Contact:

Jen Hodson
NantKwest
Telephone: 562-397-3639
Email: Press@NantKwest.com